US-based Vanda Pharmaceuticals unveiled US FDA approval for Bysanti (milsaperidone) indicated to treat schizophrenia in adults and the acute treatment of manic or mixed episodes associated with bipolar I disorder. The oral atypical antipsychotic has been cleared as a first-line pharmacological option in these indications, marking the first approval of a new chemical entity for Vanda in psychiatric disorders and expanding its CNS portfolio.

Bysanti is formulated as an oral tablet for once-daily administration in adult patients diagnosed with schizophrenia or bipolar I disorder experiencing manic or mixed episodes. The active ingredient, milsaperidone, is the active metabolite (or closely related prodrug/active form) of iloperidone – a drug marketed by Vanda under the brand name Fanapt that was previously approved in 2009 for schizophrenia and subsequently for bipolar I disorder. As such, the development of Bysanti has focused on a bridging strategy leveraging bioequivalence to iloperidone and the extensive prior iloperidone efficacy/safety database rather than a fully de novo schizophrenia development program for milsaperidone itself.

Milsaperidone rapidly interconverts to iloperidone following administration, producing dual active moieties that antagonize dopamine D2 and serotonin 5-HT2A receptors alongside alpha1-adrenergic receptors, pathways implicated in psychosis, mood dysregulation, and behavioral activation. These receptor targets are central to the pathophysiology of schizophrenia and bipolar disorder, where dysregulated dopaminergic signaling contributes to positive symptoms including hallucinations and mania. While Vanda is building on Fanapt’s pharmacological lineage, milsaperidone is classified as a distinct new chemical entity with patent protection until 2044, as per the press release.

Industry context

Current standards of care in schizophrenia and bipolar I disorder include atypical antipsychotics such as risperidone, olanzapine, and aripiprazole, many of which act through similar receptor pathways but differ in receptor binding affinities and tolerability profiles. The approval of milsaperidone adds to a growing group of receptor-modulating oral therapies that aim to balance antipsychotic efficacy with tolerability considerations in long-term psychiatric management.

The therapy joins a competitive landscape that includes several innovative or recently approved agents for schizophrenia and bipolar disorder:

  • Karuna Therapeutics’ xanomeline–trospium combination (KarXT), a muscarinic receptor agonist–antagonist combination approved by the US FDA for schizophrenia based on Phase III EMERGENT trial data.
  • Intra-Cellular Therapies’ lumateperone (Caplyta), a serotonin-dopamine modulator approved for schizophrenia and bipolar depression.
  • Sunovion Pharmaceuticals’ ulotaront, a TAAR1 agonist currently in Phase III development for schizophrenia.